-->

Tech Seeker (TS)

Agenus Inc (AKA:Antigenics LLC~Antigenics Inc)
Profile last edited on: 6/19/2013

Novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases
TS Type
Small Corporation
Status
Inactive
Year Founded
1994
Last Involved Year
2001

Key People / Management

Location Information

3 Forbes Road
Lexington, MA 02421
   (781) 674-4400
   www.agenusbio.com

Public Profile

Agenus Inc., (NASDAQ:AGEN) is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
350
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : AGEN
Received SBIR $$
Yes

SBIR firms in the news

There are no news available.